Brief: Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial
08/07/2025 12:26
July 8 (Reuters) - ProKidney Corp PROK.O: PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL Source text: ID:nGNX68jypy Further company coverage: PROK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prokidney
See all newsProkidney Corp reports results for the quarter ended September 30 - Earnings Summary
ProKidney Q3 loss widens on higher R&D costs
Brief: ProKidney Q3 Operating Income USD -53.758 Million
Brief: Prokidney Corp Enters Open Market Sale Agreement With Jefferies
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise